A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

作者：Iqbal Syma^*; Lenz Heinz Josef; Gandara David R; Shibata Stephen I; Groshen Susan; Synold Timothy W; Newman Edward M

来源：Cancer Chemotherapy and Pharmacology, 2013, 72(1): 85-91.

DOI：10.1007/s00280-013-2171-4

• Phase I
• Oxaliplatin
• Docetaxel
• Oxaliplatin and Docetaxel

The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m(2) preceded by escalating doses of docetaxel 60 mg/m(2) (75, 90, 100 mg/m(2)) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m(2) with oxaliplatin 130 mg/m(2).

• 出版日期2013-7